Good morning. In today’s news — one biotech got a third consecutive rejection from the FDA, and a group of analysts think that Eli Lilly’s stock is overvalued. Also, a Huntington’s researcher speaks on the UniQure-FDA fray and J&J scores a psoriasis pill approval.
Huntington’s researcher treads (lightly) into UniQure-FDA fray
From my colleague Andrew Joseph: When the biotech UniQure last year said that its experimental gene therapy for Huntington’s disease had slowed the progression of the untreatable condition by 75%, Ed Wild, a longtime Huntington’s clinician at University College London and one of the trial’s investigators, described the outcomes as “the result we’ve been waiting for.”
A lot, of course, has changed since then.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
